Oncotarget

Research Papers:

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

Yue-Lun Zhang, Jin-Qiu Yuan, Kai-Feng Wang, Xiao-Hong Fu, Xiao-Ran Han, Diane Threapleton, Zu-Yao Yang, Chen Mao _ and Jin-Ling Tang

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:78985-78993. https://doi.org/10.18632/oncotarget.12587

Metrics: PDF 1615 views  |   HTML 1278 views  |   ?  


Abstract

Yue-Lun Zhang1,2, Jin-Qiu Yuan1,2, Kai-Feng Wang3, Xiao-Hong Fu1,2, Xiao-Ran Han1,2, Diane Threapleton1, Zu-Yao Yang1,2, Chen Mao1,2, Jin-Ling Tang1,2

1Division of Epidemiology, The Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China

2Shenzhen Municipal Key Laboratory for Health Risk Analysis, Shenzhen Research Institute of The Chinese University of Hong Kong, Shenzhen, Guangdong Province, China

3Division of Epidemiology, School of Public Health and Tropical Medicine, Southern Medical University, Guangzhou, Guangdong Province, China

Correspondence to:

Chen Mao, email: maochen@cuhk.edu.hk

Jin-Ling Tang, email: jltang@cuhk.edu.hk

Keywords: non-small cell lung cancer, epidermal growth factor receptor, prevalence, systematic review, meta-analysis

Received: May 17, 2016    Accepted: September 25, 2016    Published: October 12, 2016

ABSTRACT

Objectives: Estimate the epidermal growth factor receptor (EGFR) mutation prevalence in all non-small cell lung cancer (NSCLC) patients and patient subgroups.

Results: A total of 456 studies were included, reporting 30,466 patients with EGFR mutation among 115,815 NSCLC patients. The overall pooled prevalence for EGFR mutations was 32.3% (95% CI 30.9% to 33.7%), ranging from 38.4% (95% CI: 36.5% to 40.3%) in China to 14.1% (95% CI: 12.7% to 15.5%) in Europe. The pooled prevalence of EGFR mutation was higher in females (females vs. males: 43.7% vs. 24.0%; OR: 2.7, 95% CI: 2.5 to 2.9), non-smokers (non-smokers vs. past or current smokers: 49.3% vs. 21.5%; OR: 3.7, 95% CI: 3.4 to 4.0), and patients with adenocarcinoma (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8).

Materials and Methods: PubMed, EMBASE, and the Cochrane Library were searched to June 2013. Eligible studies reported EGFR mutation prevalence and the association with at least one of the following factors: gender, smoking status and histology. Random-effects models were used to pool EGFR mutation prevalence data.

Conclusion: This study provides the exact prevalence of EGFR mutations in different countries and NSCLC patient subgroups.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 12587